Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Part of paid clinical trials in Duarte, California.

Sponsor
Massachusetts General Hospital
Study ID
NCT03674047
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Other Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • ruxolitinib — DRUG
    Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body

Study Details

This research study is studying a drug as a possible treatment for Bronchiolitis Obliterans Syndrome (BOS) after having an Allogeneic Hematopoietic Cell Transplantation (HCT).

Key Dates

Start date
Apr 19, 2019
Status verified
Nov 2025
Primary completion
Dec 2, 2022
Completion
Dec 31, 2025

Study Design

Enrollment
50 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: newly-diagnosed BOS
    -Participants will take ruxolitinib twice every day
  • Experimental: Established BOS
    -Participants will take ruxolitinib twice every day

Primary Outcome Measure

absolute FEV1 increase [ Time Frame: 3 Months ]

Locations (7)

FacilityCityStateZIPSite coordinators
City of Hope Cancer CenterDuarteCalifornia91010-
H. Lee Moffitt Cancer CenterTampaFlorida33612-
Massachusetts General HospitalBostonMassachusetts02114-
Cleveland ClinicClevelandOhio44195-
Huntsman Cancer InstituteSalt Lake CityUtah84112-
Fred Hutchinson Cancer CenterSeattleWashington98109-
Medical College of WisconsinMilwaukeeWisconsin53226-

Find similar trials in Duarte, CA

By research site
City of Hope Cancer Center· Duarte, CAH. Lee Moffitt Cancer Center· Tampa, FLMassachusetts General Hospital· Boston, MACleveland Clinic· Cleveland, OHHuntsman Cancer Institute· Salt Lake City, UTFred Hutchinson Cancer Center· Seattle, WA

Related Studies